NCT02089763View on ClinicalTrials.gov

Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

pegylated recombinant human arginase

Trial Locations (1)

Unknown

Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong

Sponsors
All Listed Sponsors
collaborator

Chinese University of Hong Kong

OTHER

collaborator

The University of Hong Kong

OTHER

lead

Bio-Cancer Treatment International Limited

INDUSTRY

NCT02089763 - Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer | Biotech Hunter | Biotech Hunter